MARKET

CERS

CERS

Cerus Corp
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.96
+0.11
+1.53%
Opening 11:46 08/12 EDT
OPEN
6.81
PREV CLOSE
6.85
HIGH
6.97
LOW
6.81
VOLUME
324.08K
TURNOVER
--
52 WEEK HIGH
7.56
52 WEEK LOW
2.710
MARKET CAP
1.16B
P/E (TTM)
-15.7746
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CERS stock price target is 9.13 with a high estimate of 10.00 and a low estimate of 8.00.

EPS

CERS News

More
Cerus announces sales milestone for Intercept system
Cerus (CERS) has announced that its INTERCEPT Blood Systems disposable kit shipments have surpassed 7.5M treatable platelet and plasma doses, since commerc
seekingalpha · 4d ago
Cerus INTERCEPT Blood System Kit Shipments Surpass 7.5 Million Treatable Platelet and Plasma Doses Since Launch
Cerus Corporation (Nasdaq:CERS) announced today that INTERCEPT Blood Systems disposable kit shipments have surpassed 7.5 million treatable platelet and plasma doses globally since commercial launch.
Business Wire · 5d ago
Cerus Corporation (CERS) Q2 2020 Earnings Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the CERUS Corp. Q2 2020 Earnings Conference Call. With me on the call are Obi Greenman, Cerus' President and Chief Executive Officer; Dr. Nina Mufti, Cerus' Vice President, Development and Red Bl
Motley Fool · 08/05 06:01
Cerus EPS beats by $0.02, beats on revenue
Cerus (NASDAQ:CERS): Q2 GAAP EPS of -$0.09 beats by $0.02. Revenue of $26.8M (+47.2% Y/Y) beats by $6.21M. Shares +5.5%. Press Release
seekingalpha · 08/05 01:05
Cerus (CERS) Reports Q2 Loss, Tops Revenue Estimates
Cerus (CERS) delivered earnings and revenue surprises of 10.00% and 0.01%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/04 21:15
Cerus Reaffirms FY20 Sales Guidance of $89M-$93M Vs. $112.8M Est.
Benzinga · 08/04 20:30
Cerus Q2 EPS $(0.09) Beats $(0.11) Estimate, Sales $26.80M Beat $25.89M Estimate
Cerus (NASDAQ:CERS) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.11) by 18.18 percent. This is a 30.77 percent increase over losses of $(0.13) per share from the same
Benzinga · 08/04 20:29
Cerus Corporation Announces Record Second Quarter 2020 Results
Cerus Corporation (Nasdaq: CERS) today announced financial results for the second quarter ended June 30, 2020.
Business Wire · 08/04 20:02

Industry

Medical Equipment, Supplies & Distribution
+1.59%
Healthcare Equipment & Supplies
+1.69%

Hot Stocks

Symbol
Price
%Change

About CERS

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company's INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company's INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company's INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.
More

Webull offers kinds of Cerus Corporation stock information, including NASDAQ:CERS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CERS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CERS stock methods without spending real money on the virtual paper trading platform.